Biological Activity
R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) (Ki = 1, 3, and 1 nM for CDK1, CDK2, and CDK4, respectively) with excellent in vitro cellular potency that inhibits the growth of various human tumor cell lines.
Targets
Target | Value |
---|---|
CDK4/CyclinD1 | ki: 1nM |
CDK1/CyclinB | ki: 2nM |
CDK2/CyclinE | ki: 3nM |
PKA | ki: >5μM |
PKB | ki: >5μM |
PKCα | ki: >5μM |
PKCβ | ki: >5μM |
Fyn | ki: >5μM |
EphB3 | ki: >5μM |
SGK | ki: >5μM |
KDR | ki: >5μM |
FGFR | ki: >5μM |
EGFR | ki: >5μM |
PDGFR | ki: >5μM |
IGFR | ki: >5μM |
Src | ki: >5μM |
FAK | ki: >5μM |
AuroraA | ki: >5μM |
GSK-3β | ki: 8μM |
p38 | ki: >50μM |
MAPK2 | ki: >50μM |
In vitro (25°C) | DMSO | 56 mg/mL (126.85 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 1% hydroxyethyl cellulose+0.2% Tween 80 | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.65 mL | 113.26 mL | 226.53 mL |
0.5 mM | 4.53 mL | 22.65 mL | 45.31 mL |
1 mM | 2.27 mL | 11.33 mL | 22.65 mL |
5 mM | 0.45 mL | 2.27 mL | 4.53 mL |
*The above data is based on the productmolecular weight 441.45. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Catalog Num | A11190 |
---|---|
Actions | Inhibitor |
CAS No. | 741713-40-6 |
Formula | C18H21F2N5O4S |
M. Wt | 441.45 |
Purity | >98% |
Synonyms | R-547 |
SMILES | COC1=C(C(=C(C=C1)F)F)C(=O)C2=CN=C(N=C2N)NC3CCN(CC3)S(=O)(=O)C |
Storage | Store lyophilized at -20ºC, keep desiccated. |
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD 0332991 HCl (Palbociclib)
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activit…
AT7519 HCl
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
NVP-LCQ195
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
BS-181
BS-181 is a potential anti-tumor agent as CDK7 inhibitor.
P276-00
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
Dinaciclib (SCH 727965)
Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 …
CVT-313
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 2…
PHA-793887
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity ag…
Keywords:buy R547 | R547 Supplier | purchase | cost | manufacturer | order | distributor | buy 741713-40-6| 741713-40-6 Supplier | purchase 741713-40-6 | 741713-40-6 cost | 741713-40-6 manufacturer | order 741713-40-6 | 741713-40-6 distributor